Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 i 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine - A randomized, double-blind, placebo controlled trial;Hamowanie pohistaminowego ba̧bla, rumienia i włoś niczkowego przepływu skórnego po jednorazowym podaniu zalecanej dawki: 10 mg cetyryzyny, 5 mg desloratadyny, 120 i 180 mg feksofenadyny, 5 mg lewocetyryzyny i 10 mg loratadyny - Badanie randomizowane, kontrolowane placebo

Polski Merkuriusz Lekarski

Volumn 21, Issue 125, 2006, Pages 443-448

  Kruszewski, Jerzy ^a,b   Kłos, Krzysztof ^a,b   Sułek, Kazimierz ^a,b  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF NATIONAL DEFENSE   (Poland)

Author keywords

Antihistamines; Laser Doppler flowmetry

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; DESLORATADINE; FEXOFENADINE; HISTAMINE; LEVOCETIRIZINE; LORATADINE; PLACEBO; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; PIPERAZINE DERIVATIVE; TERFENADINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; DRUG POTENCY; HUMAN; HUMAN EXPERIMENT; LASER DOPPLER FLOWMETRY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN BLOOD FLOW; SKIN MANIFESTATION; URTICARIA; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MALE; ORAL DRUG ADMINISTRATION; SKIN; SKIN TEST; TREATMENT OUTCOME; VASCULARIZATION;

ADMINISTRATION, ORAL; ADULT; CETIRIZINE; DOUBLE-BLIND METHOD; HISTAMINE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LASER-DOPPLER FLOWMETRY; LORATADINE; MALE; PIPERAZINES; PLACEBOS; SKIN; SKIN TESTS; TERFENADINE; TREATMENT OUTCOME; URTICARIA;

EID: 33845284238     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Atkins P., Merton H., Karpink P. i wsp.: Azelastine inhibition of skin test reactivity in humans. Allergy Clin. Immunol., 1985, 75, 167-169.
2. Barbanoj M.J., Antonijoan R.M., Garcia-Gea C. i wsp.: A study comparing the inhibitory effects of single and repeated oral doses of ebastine and fexofenadine against histamine-induced skin reactivity. Int. Arch. Allergy. Immunol., 2003, 132, 263-267.
3. Barbanoj M.J., Gracia-Gea C., Morte A. i wsp.: Central and peripherial evaluation of Rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology, 2004, 50, 311-321.
4. Berkowitz R.B., Dockhorn R., Lockey R. i wsp.: Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. Ann. Allergy Asthma Immunol., 1996, 76, 363-368.
5. Bousquet J., Chanal I., Murrieta M. i wsp.: Lack of subsensitivity to mizolastine over 8-week treatment. Allergy, 1996, 51, 251-256.
6. Bousquet J., Chnal I., Skassa-Brociek W. i wsp.: Lack of subsensitivity to loratadine during long-term dosing during 12 weeks. J. Allergy Clin. Immunol., 1990, 86, 248-253.
7. Burns R.B., Shelanski M.V.: Histamine wheal and flare inhibition by clemastine fumarate. Ann. Allergy, 1977, 38, 339-344.
8. Carey W., Warrington S., Boyce M. i wsp.: Inhibition of the histamine wheel by ebastine compared with cetirizine, fexofenadine and loratadine at steady state. Drugs Exp. Clin. Res., 2002, 28, 243-247.
9. Clough G.F., Boutsiouki P., Church M.K.: Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy, 2001, 56, 985-988.
10. De Weck A.L., Derer T., Bahre M. i wsp.: Investigation of the anti-allergic activity of azelastnie on the immediate and late-phase reactions to allergens and histamine using teletermography. Clin. Exp. Allergy, 2000, 30, 283-287.
11. Denham K.J., Boutsiouki P., Clough G.F. i wsp.: Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare, and itch in human skin. Inflammation Res., 2003, 52, 424-427.
12. Devalia J.L., De Vos C., Hantte F. i wsp.: A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and UB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy, 2001, 56, 50-57.
13. Fadel R., Herpin-Richard N., Dufresne F. i wsp.: Pharmacological modulation by cetirizine and loratadine of antigen and histamine-induced skin wheals and flares and late accumulation of eosinophils. J. Int. Med. Res., 1990, 18, 366-371.
14. Galant S.P., Bullock J., Wong D. i wsp.: The inhibitory effect of antiallergy drugs on allergen and histamine induced wheal and flare response. J. Allergy Clin. Immunol., 1973, 51, 11-21.
15. Gendreau-Reid L., Simons K.J., Simons F.E. : Comparison of the suppressive effect of astemizole, terfenadine, and hydroxyzine on histamine-induced wheals and flares in humans. J. Allergy Clin. Immunol., 1986, 77, 335-340.
16. Giannaras A., Selig W., Ellis J. i wsp.: The effect of a novel, dual function histamine H1 receptor antagonist 5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur. J. Pharmacol., 2005, 506, 265-271.
17. Gibson J.R., Medder K.T., McDonnell K.A. i wsp.: The effect of orally administered triprolidine and pseudoephedrine singly and combined on histamine-induced skin reactions. Eur. J. Clin. Pharmacol., 1982, 22, 411-412.
18. Grant A.J., Riethuisen J-M., Moulaert B. i wsp.: A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine and placebo: suppression o histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann. Allergy Asthma. Immunol., 2002, 88, 190-197.
19. Grant J.A., Danielson L., Rihoux J.P. i wsp.: A comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadne, and loratadine versus placebo in suppressing the cutaneous response to histamine. Int. Arch. Allergy Immunol., 1999, 118, 339-340.
20. Grant J.A., Danielson L., Rihux J.P. i wsp.: A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy, 1999, 54, 700-707.
21. Hagermark O., Strandberg K., Gronneberg R.: Effects of histamine receptor antagonists on histamine-induced responses in human skin. Acta Derm. Venereol., 1979, 59, 297-300.
22. Hindmarch I., Johnson S., Meadows R. i wsp.: The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr. Med. Res. Opin., 2001, 17, 241-255.
23. Kaliner M.A., White M.V., Economides A. i wsp.: Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Ann. Allergy Asthma Immunol., 2003, 90, 629-634.
24. Kassem N., Roman I., Gural R. i wsp.: Effects of loratadine (SCH 29851) in suppression of histamine-induced ski wheals. Ann. Allergy, 1988, 60, 505-507.
25. Kontou-Fili K., Paleologos G., Herakleous M.: Suppression of histamine-induced skin reactions by loratadine and cetirizine diHCl. Eur. J. Clin. Pharmacol., 1989, 36, 617-619.
26. Kruszewski J., Silny W., Mazurek H. i wsp.: Testy skórne, w: Standardy w Alergologii cz. I. The UCB Institute of Allergy, Belgium, 2003, 9-26.
27. Labrecque M., Ghezzo H., L'Archeveque J. i wsp.: Duration of effect of loratadine and terfenadine administered once a day for one week on cutaneous and inhaled reactivity to histamine. Chest, 1993, 103, 777-781.
28. Lahti A., Haapaniemi T.: Initiation of the effects of acrivastine and cetirizine on histamine-induced wheals and itch in human skin. Acta Derm. Venerol. (Stockh), 1993, 73, 350-351.
29. Lockwood J.M., Wilkins B.W., Halliwill J.R. i wsp.: H1 receptor-mediated vasodilatation contributes to postexercise hypotension. J. Physiol., 2005, 563, 633-642.
30. Long W.F., Taylor RJ., Wagner C.J. i wsp.: Skin test suppression by antihistamines and the development of subsensitivity. J. Allergy Clin. Immunol., 1985, 76, 113-117.
31. Ludyga T., Urbanek T., Zaniewski M. i wsp.: Zastosowane laserowego przepływomierza dopplerowskiego (LDF) w diagnostyce klinicznej. W pod red Ziaja K.: Mikrokra̧żenie zarys chorób układu włośniczkowego. Alfa-Medica Press. Bielsko Biała 1997, 43-47.
32. Nelson H.S., Bucher B., Buchmaier A. i wsp.: Suppression of the skin reaction to histamine by ebastine. Ann. Allergy Asthma Immunol., 1995, 74, 442-447.
33. Petersen L.J., Bindslev-Jensen C., Polusen L.K. i wsp.: Time of onset of action of acrivastine in the skin of pollen-allergic subjects. A double-blind, randomized, placebo-controlled comparative study. Allergy, 1994, 49, 27-30.
34. Petersen L.J., Church M.K., Rihoux J. i wsp.: Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. Allergy, 1999, 54, 607-611.
35. Pinquier J.L., Caplain H., Cabanis M.J. i wsp.: Inhibition of histamine-induced ski wheal and flare after 5 days of mizolastine. J. Clin. Pharmacol., 1996, 36, 72-78.
36. Purohit A., Duvernelle C., Melac M. i wsp.: Twenty-for hours of activity of cetirizine and fexofenadine in the skin. Ann. Allergy Asthma Immunol., 2001, 86, 387-392.
37. Purohit A., Melac M., Pauli G. i wsp.: Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br. J. Clin. Pharmacol., 2003, 56, 388-394.
38. Rafferty P., Harroson P.J., Aurich R. i wsp.: The in vivo potency and selectivity of azelastine as an H1 histamine-receptor antagonist in human airways and skin. J. Allergy Clin. Immunol., 1988, 82, 1113-1118.
39. Ramboer I., Bumbacea R., Lazarescu D. i wsp.: Cetirizine and loratadine: a comparison using the ED-50 in skin reactions. J. Int. Med. Res., 2000, 28, 69-77.
40. Rao K.S., Menon P.K., Hilman B.C. i wsp.: Duration of the suppressive effect of tricyclic antidepressants on histamine-induced wheal-and-flare reactions in human skin. J. Allergy Clin. Immunol., 1988, 82, 752-757.
41. Rihoux J.P., Van Neste D.J.: Quantitative time course study of the skin response to histamine and the effect of H1 blockers. A 3-week crossover double-blind comparative trial of cetirizine and terfenadine. Dermatologies, 1989, 179, 129-134.
42. Rivest J., Despontin K., Grys L. i wsp.: Pharmacological modulation by cetirizine and ebastine of the cutaneous reactivity to histamine. Dermatologica, 1991, 183, 208-211.
43. Roman I.J., Kassem N., Gural R.P. i wsp.: Suppression of histamine-induced wheat response by loratadine (SCH 29851) over 28 days in man. Ann. Allergy, 1986, 57, 253-256.
44. Rosenzwejg P., Caplain H., Chaufour S. i wsp.: Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine ad placebo in healthy volunteers. Br. J. Clin. Pharmacol., 1995, 40, 459-465.
45. Shall L., Thompsomi D.A., Barkley A.S.J. i wsp.: Comparative inhibition profiles of three non-sedating antihistamines assessed by an extended Lewis model. Clin. Exp. Allergy, 1992, 22, 711-716.
46. Simons F.E.R., Mcmillan J.L., Simons K.J.: A double-blind, single dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizol, and chlorpheniramine versus placebo: Suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J. Allergy Clin. Immunol., 1990, 86, 540-547.
47. Simons F.E.R., Johnston L., Gu X. i wsp.: Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast. Ann. Allergy Asthma Immunol., 2001, 86, 44-50.
48. Simons F.E.R., Murray H.E., Simons K.J.: Quantitation of H1-receptor antagonists in skin and serum. J. Alergy Clin. Immunol., 1995, 95, 759-764.
49. Simons F.E.R., Semus M., Goritz S.S. i wsp.: H1-antihistamine activity of cetirizine and fexofenadine in allergic children. Pediatr. Allergy Immunol., 2003, 14, 207-211.
50. Simons F.E.R., Silver N., Gu X. i wsp.: Skin concentrations of H1-receptor antagonist. J. Allergy Clin. Immunol., 2001, 107, 526-530.
51. Simons F.E.R., Simons K.J.: Clinical pharmacology of H1-antihistamines. In: Histamine and H1-Antihistamines in Allergic Disease (ed. Simons F.E.R.). Marcel Dekker, Inc. New York. 2002, 141-178.
52. Simons F.E.R., Simons K.J.: Peripheral H1-blockade effect of fexofenadine. Ann. Allergy Asthma Immunol., 1997, 79, 530-532.
53. Simons F.E.R.: H1-Antihistamines: more relevant than ever in the treatment of allergic disorders. J. Allergy Clin. Immunol., 2003, 112, supl. 4, S42-S52.
54. Town G.I., Holgate S.T.: Comparison of the effect of loratadine on the airway and skin response to histamine, metacholine and allergen in subjects with asthma. J. Allergy Clin. Immunol., 1990, 86, 886-893.
55. Wood-Backer R., Holgate S.T. i wsp.: The comparative actions and adverse effect profiles of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J. Allergy Clin. Immunol., 1993, 91, 1005-1014.
56. Zakrzewski A., Kruszewski J., Klos K. i wsp.: Zastosowanie włośniczkowej przepływometrii laserowej do oceny punktowych testów skórnych z roztworami histaminy i alergenami. Pol. Merk. Lek., 2004, 105, 282-286.